Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors

American Journal of Medicine

Volumn 110, Issue 3 SUPPL. 1, 2001, Pages 33-42

  Whelton, Andrew ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b C/o Universal Clinical Research Center Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; SULINDAC; TIAPROFENIC ACID;

ACUTE KIDNEY FAILURE; AGED; CLINICAL TRIAL; CRUSH SYNDROME; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; ELECTROLYTE DISTURBANCE; HOMEOSTASIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY PAPILLA NECROSIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0035910978     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00699-9     Document Type: Review

References (72)

1. Nonsteroidal anti-inflammatory drugs: Effects on kidney function
2. Nonsteroidal antiinflammatory drugs: Effects on kidney function
3. Nonsteroidal antiinflammatory drugs: Proposed guidelines for monitoring toxicity
4. Clinical implications of prostaglandin and thromboxane A2 formation (1)
5. Clinical implications of prostaglandin and thromboxane A2 formation (2)
6. Acute oliguric renal failure produced by indomethacin: Possible mechanisms
7. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome
8. Irreversible renal failure after indomethacin in steroid-resistant nephrosis
9. Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus
10. Ibuprofen-induced acute renal failure with acute tubular necrosis
11. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
12. Cyclooxygenase in biology and disease
13. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
14. Nonsteroidal anti-inflammatory drugs and their effects: The importance of COX "selectivity."
15. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
16. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal anti-inflammatory drug-related nephrotoxicity
17. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells
18. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
19. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
20. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells
21. Renal syndromes associated with nonsteroidal antiinflammatory drugs
22. Nonsteroidal anti-inflammatory drugs: Effects on kidney function
23. Ibuprofen-induced hyponatremia
24. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure
25. Non-steroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure
26. Patterns of tubulo-interstitial damage associated with nonsteroidal anti-inflammatory drugs
27. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs
28. Renal papillary necrosis due to ibuprofen
29. Papillary necrosis following phenylbutazone ingestion
30. Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy
31. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure
32. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis
33. Blood pressure, stroke, and coronary heart disease, part 2: Short-term reductions in blood pressure - Prospective observational studies corrected for the regression dilution bias
34. The impact of nonsteroidal anti-inflammatory drugs on hypertension: Alternative analgesics for patients at risk
35. Nonsteroidal anti-inflammatory drugs and antihypertensives
36. NSAIDs and increased blood pressure: What is the clinical significance?
37. Nonsteroidal anti-inflammatory drugs and antihypertensives: Cooperative malfeasance
38. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy
39. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: A community-based cross-sectional study
40. Detection and treatment of hypertension in elderly individuals
41. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics
42. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. An unrecognized public health problem
43. The classification of cyclooxygenase inhibitors
44. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
45. Celecoxib, a COX-2-specific inhibitor: The clinical data
46. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?
47. Celecoxib for the treatment of pain and inflammation: The preclinical and clinical results
48. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
49. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
50. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
51. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis
52. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6-week double-blind, placebo-controlled pilot study of rofecoxib
53. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor - Pharmacological and biochemical profiles
54. Rofecoxib
55. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
56. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
57. An approach to the interpretation of drug concentrations in the kidney
58. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats
59. Renal safety and tolerability of celecoxib, a novel cyclooxygenase (COX)-2 inhibitor
60. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
61. Rofecoxib product information
62. Are selective COX-2 inhibitors nephrotoxic?
63. Acute renal failure associated with rofecoxib
64. Changes in renal function with aging
65. Aging and the kidney
66. Effects of aging and drugs on normal renal function
67. Nephrotoxicity of common drugs used in clinical practice
68. Identification of risk for renal insufficiency from non-steroidal anti-inflammatory drugs
69. Renal effects of nonsteroidal anti-inflammatory drugs: Heightened risk to the elderly
70. Effects of celecoxib and naproxen on renal function in the elderly
71. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
72. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial